News &amp; Updates

Infantile haemangioma (IH) ulceration may occur in some patients receiving oral propranolol, reports a study, noting independent risk factors for such condition.

Regular walking reduces MACE in individuals with hypertension

21 Oct 2026 by

In a large study using UK Biobank data, incremental increases in daily step count are associated with a significantly lower risk of major adverse cardiovascular events (MACE) in adults with hypertension, especially when accrued at a higher stepping intensity.

21 Oct 2026

Calcium supplementation does little to reduce pre-eclampsia risk

Initiating supplementation with calcium before or during pregnancy falls short of reducing the risk of pre-eclampsia, according to an individual participant data (IPD) meta-analysis.

Faecal transplant no boon for improving IBS, targeted microbiome modulation needed

Faecal microbiota transplantation (FMT) shows no evidence of clinical benefit in the treatment of irritable bowel syndrome (IBS) in the phase III REFIT2 trial.

Polygenic risk scores may predict diabetes onset in adults

An association exists between polygenic risk scores (PRS) and diabetes risk, irrespective of traditional risk factors, according to a study in Japanese general populations.

Long-term bimekizumab use for axSpA proven safe, efficacious in two phase III studies

Long-term use of bimekizumab is well tolerated and does not raise new safety concerns in patients with axial spondyloarthritis (axSpA), according to two phase III studies.

20 Oct 2026

Abrocitinib tapering feasible in patients with moderate-to-severe AD

A recent study has shown the feasibility of 24-week abrocitinib tapering in well-responding patients with moderate-to-severe atopic dermatitis (AD), reducing treatment burden without compromising efficacy.

Japan study underpins ensitrelvir potential in kids with COVID-19

A phase III study from Japan demonstrates the safety and tolerability of ensitrelvir in paediatric patients with mild-to-moderate COVID-19.

20 Oct 2026

Add-on sotatercept beneficial in paediatric pulmonary hypertension

Sotatercept, when added to background therapy, helps improve outcomes for children with pulmonary hypertension, as shown in a retrospective study.

TG103 noninferior to dulaglutide for HbA1c reduction in Chinese adults with T2D

Once-weekly TG103, a novel long-acting GLP-1*/Fc fusion protein, demonstrates noninferiority to dulaglutide in reducing HbA_1c in Chinese patients with type 2 diabetes (T2D) inadequately controlled on metformin, according to a phase III trial presented at EASD 2026.